List of Bryhali drug patents
Bryhali is owned by Bausch.
Bryhali contains Halobetasol Propionate.
Bryhali has a total of 2 drug patents out of which 0 drug patents have expired.
Bryhali was authorised for market use on 06 November, 2018.
Bryhali is available in lotion;topical dosage forms.
Bryhali can be used as topical treatment of plaque psoriasis in adults.
The generics of Bryhali are possible to be released after 02 November, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
BRYHALI family patents
7
United States
2
Canada
2
Korea, Republic of
1
Israel
1
Russia
1
Japan
1
Brazil
1
Mexico
1
Australia
1
New Zealand
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic